HOWL News and Press, Werewolf Therapeutics Inc. From 11/07/23

2023-11-07 08:36:07 ET Losers: Ventyx Biosciences ( VTYX ) -76% announces results from the phase 2 trial of VTX958 in patients with moderate to severe plaque Psoriasis and provides corporate update. Alto Ingredients ( ALTO ) -50% reports third quarter 2023 re...

2023-11-06 17:14:34 ET Summary Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicit...

2023-11-03 14:08:27 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- The following companies were among the listings that we covered this week; Verve Therapeutics Inc (NASDAQ: VERV), Cellectis (NASDAQ: CLLS), Palantir Technologies (NYSE: PLTR), Werewolf Therapeutics (N...

2023-11-03 12:32:00 ET Summary Oct. nonfarm payrolls came in weaker than expected, unemployment rate ticked up to 3.9%. AI will likely make all jobs obsolete at some point in the future - Elon Musk. BofA releases two feast and famine charts from the broader market. L...

2023-11-03 12:14:31 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (...

2023-11-03 09:53:11 ET DENVER, Colo., Nov. 3, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Werewolf Therapeutics Inc (NASDAQ: HOWL), Plus Therapeutics Inc (NASDAQ: PSTV), Tenon Medical Inc (NASDAQ: TNO...

2023-11-03 08:04:12 ET Shares of Werewolf Therapeutics ( NASDAQ: HOWL ) added ~34% after announcing two partial remissions in an early-stage clinical program for WTX-124, one of its lead cancer candidates targeted at solid tumors. Citing early data, Watertown, Massachusetts-...

2023-11-03 08:01:37 ET DENVER, Colo., Nov 3, 2023 ( www.247marketnews.com )- Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported, this morning, preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-12...

Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the ...

2023-11-02 08:37:27 ET Losers: Confluent CFLT -34% after Q3 earning release . Remitly Global RELY -23% after Q3 earning release . Acurx Pharmaceuticals ( ACXP ) -18% announces positive top-line Ibezapolstat phase 2 efficacy results with 96% clinical c...